Evidence map›Paper›PMID 38956674›Full record

ArticleCost effectiveness and resource allocation : C/E2024

Net costs of breast cancer in Colombia: a cost-of-illness study based on administrative claims databases.

Gabriel Fernando Torres, Brigitte Alejandra Alarcón, Juan Manuel Reyes-Sanchez, Natalia Castaño-Gamboa, Giancarlo Buitrago

Abstract read
In one paragraph

Article in Cost effectiveness and resource allocation : C/E, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Gabriel Fernando TorresInstituto de Investigaciones Clínicas, Universidad Nacional de Colombia, Carrera 45 # 26-85, Bogotá, 111321, Colombia. gftorresa@unal.edu.co.
Brigitte Alejandra AlarcónPfizer S.A.S, Av. Suba #95-66, Bogotá, 112111, Colombia.
Juan Manuel Reyes-SanchezPfizer S.A.S, Av. Suba #95-66, Bogotá, 112111, Colombia.ORCID http://orcid.org/0000-0003-0806-7173
Natalia Castaño-GamboaPfizer S.A.S, Av. Suba #95-66, Bogotá, 112111, Colombia.ORCID http://orcid.org/0000-0001-7383-6800
Giancarlo BuitragoInstituto de Investigaciones Clínicas, Universidad Nacional de Colombia, Carrera 45 # 26-85, Bogotá, 111321, Colombia.

Funding

Pfizer (Colombia) 2021-237
6 · The paper itself

Abstract

backgroundBreast Cancer (BC) is associated with substantial costs of healthcare; however, real-world data regarding these costs in Colombia is scarce. The contributory regime provides healthcare services to formal workers and their dependents and covers almost half of the population in Colombia. This study aims to describe the net costs of healthcare in women with BC covered by the contributory regime in Colombia in 2019 from the perspective of the Colombian Health System.

methodsThe main data source was the Capitation Sufficiency Database, an administrative database that contains patient-level data on consumption of services included in the National Formulary (PBS, in Spanish Plan de Beneficios en Salud). Data on consumption of services not included in the PBS (non-PBS) were calculated using aggregated data from MIPRES database. All direct costs incurred by prevalent cases of BC, from January 1 to December 31, 2019, were included in the analysis. The net costs of the disease were estimated by multiplying the marginal cost and the expected number of cases with BC by region and age group. Marginal costs were defined as the costs of services delivered to patients with BC after subtracting the expected costs of health services due to age, comorbidity burden or region of residence. To calculate these costs, we used Propensity Score Matching in the main analysis. All costs were expressed in 2019 international dollars. Productivity losses, transportation expenses, and caregiving costs were not included.

resultsA total of 46,148 patients with BC were identified. Total net costs were $387 million (95% CI $377 to $396 million), 60% associated with non-PBS services. Marginal costs were $8,366 (95% Confidence Interval $8,170 to $8,573), with substantial variations between regions age groups (from $3,919 for older patients in the Amazonia region to $10,070 for younger patients in the Pacific region). The costs for PBS services were higher for ambulatory services and for patients who died during 2020.

conclusionsBC imposes a substantial economic burden for the Colombian Health System with important variations in net costs between regions and age groups. Patients near death and ambulatory services were associated with higher costs of healthcare.

Indexed as

Breast cancerCost-of-illness studyNet costs

Identifiers

PMID38956674
PMCPMC11218325

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.